1. Home
  2. HEPA vs GNLN Comparison

HEPA vs GNLN Comparison

Compare HEPA & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HEPA
  • GNLN
  • Stock Information
  • Founded
  • HEPA 2013
  • GNLN 2005
  • Country
  • HEPA United States
  • GNLN United States
  • Employees
  • HEPA N/A
  • GNLN N/A
  • Industry
  • HEPA Biotechnology: Pharmaceutical Preparations
  • GNLN Durable Goods
  • Sector
  • HEPA Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • HEPA Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • HEPA 1.7M
  • GNLN 1.6M
  • IPO Year
  • HEPA N/A
  • GNLN 2019
  • Fundamental
  • Price
  • HEPA $0.17
  • GNLN $0.74
  • Analyst Decision
  • HEPA
  • GNLN
  • Analyst Count
  • HEPA 0
  • GNLN 0
  • Target Price
  • HEPA N/A
  • GNLN N/A
  • AVG Volume (30 Days)
  • HEPA 31.4M
  • GNLN 279.5K
  • Earning Date
  • HEPA 04-15-2025
  • GNLN 11-15-2024
  • Dividend Yield
  • HEPA N/A
  • GNLN N/A
  • EPS Growth
  • HEPA N/A
  • GNLN N/A
  • EPS
  • HEPA N/A
  • GNLN N/A
  • Revenue
  • HEPA N/A
  • GNLN $21,605,000.00
  • Revenue This Year
  • HEPA N/A
  • GNLN $72.27
  • Revenue Next Year
  • HEPA N/A
  • GNLN $93.46
  • P/E Ratio
  • HEPA N/A
  • GNLN N/A
  • Revenue Growth
  • HEPA N/A
  • GNLN N/A
  • 52 Week Low
  • HEPA $0.12
  • GNLN $0.70
  • 52 Week High
  • HEPA $3.33
  • GNLN $21.80
  • Technical
  • Relative Strength Index (RSI)
  • HEPA 36.41
  • GNLN 18.97
  • Support Level
  • HEPA $0.17
  • GNLN $0.70
  • Resistance Level
  • HEPA $0.19
  • GNLN $1.60
  • Average True Range (ATR)
  • HEPA 0.02
  • GNLN 0.12
  • MACD
  • HEPA 0.01
  • GNLN -0.06
  • Stochastic Oscillator
  • HEPA 28.55
  • GNLN 4.34

About HEPA Hepion Pharmaceuticals Inc.

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a distributor of vaporization products and consumption accessories in the United States. It offers a selection of stock-keeping units including vaporizers and parts, cleaning products, grinders and storage containers, pipes, rolling papers and customized lines of premium specialty packaging. The company markets and sells its products in both the business to business and business to consumer sectors of the marketplace. Its geographical segment includes the United States; Canada and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: